Karyopharm presents updated phase 2 SAIL Relapsed/Refractory AML clinical data
Karyopharm Therapeutics announced updated results from the Phase 2 SAIL study, in which deep responses to selinexor (KPT-330) allowed patients with heavily pretreated acute myeloid leukemia to proceed onto stem cell transplantation or donor lymphocyte transfusion. December 04, 2016